Table 7.

Serious adverse events

Patient	Stage	Age (years)	Biological markers	Events
29	4	3.7	MYCN amplification	Sepsis during isolation. After the first treatment arterial bleeding in the thorax due to tumour invasion of blood vessels
41	4S	0.1	MYCN amplification	Respiratory and circulatory insufficiency and subsequently died
53	4	2.3	MYCN amplification, chromosome 1p loss of heterozygosity	Severe inferior vena cava syndrome, respiratory distress, restlessness and opisthotonus
74	4	6.1	MYCN amplification, chromosome 1p loss of heterozygosity	Respiratory insufficiency due to convulsions (caused by posterior reversible encephalopathy syndrome) and anticonvulsive medication